Detection of actionable mutations in the cerebrospinal fluid and concordance/discordance with extracranial mutations in patients with metastatic breast cancer and leptomeningeal disease
Therapeutic Advances in Medical Oncology
Published online on March 17, 2026
Abstract
Therapeutic Advances in Medical Oncology, Volume 18, January-December 2026.
Background:Leptomeningeal disease (LMD) is a devastating complication of metastatic breast cancer (MBC). Metastatic tumors to the central nervous system (CNS) are not routinely assessed for the presence of actionable mutations, hence the frequency and ...
Background:Leptomeningeal disease (LMD) is a devastating complication of metastatic breast cancer (MBC). Metastatic tumors to the central nervous system (CNS) are not routinely assessed for the presence of actionable mutations, hence the frequency and ...